Pharmaceutical & Biotech in Richmond, British Columbia

Pharmaceutical effluent is defined less by its strength than by what regulators and municipal plants do not want in it. Active pharmaceutical ingredients pass through conventional biological treatment largely intact, solvents from synthesis and extraction can upset or kill a downstream biomass, and cleaning validation chemistry adds surfactants and sanitizers to every batch changeover. Pharmaceutical wastewater treatment therefore starts with segregation: identifying which streams can go to a conventional plant, which need dedicated pretreatment, and which should never enter the drain at all.

Layered compliance

For Canadian manufacturers, the compliance picture layers municipal sewer bylaws, provincial environmental approvals and, increasingly, customer and parent-company sustainability audits that ask harder questions than the bylaw does. A plant can be legally compliant and still fail a corporate audit over API discharge, which is pushing the sector toward treatment levels beyond the regulatory floor.

Why MBR fits this sector

The technology that fits this sector best is the membrane bioreactor. An MBR combines biological treatment with ultrafiltration in one step, holds a high biomass concentration that resists shock loads, and produces an effluent clean enough for reverse osmosis polishing where API removal or water reuse is the goal. An MBR followed by an industrial reverse osmosis system is the standard answer when a pharmaceutical plant needs to close the loop on process water or meet a discharge target that conventional treatment cannot reach. Upstream of the biology, equalization and pH correction protect the biomass from batch chemistry, and activated carbon or advanced oxidation handles specific recalcitrant compounds where analysis shows they persist.

High-purity reject streams

Sterile and biologics facilities bring their own wrinkle: clean-in-place and water-for-injection systems generate high-purity reject streams that are easy to reuse if they are kept separate from the dirty drains.

Packages and pilots

We supply MBR packages, RO skids, equalization systems and lab-scale pilot units for pharmaceutical and nutraceutical plants. Provide your stream inventory and analytical data, and we will propose a segregation and treatment scheme sized to your batches, with pilot testing before you commit to full scale. Contract manufacturers face a harder version of this problem, because the product mix changes with the customer list, and we design their segregation and treatment schemes with more equalization and more analytical monitoring than a single-product site would need.